Gabelli & Co Investment Advisers’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,700	Closed	-$420K	–	300
2022 Q4	$420K	Buy	+20,700	New	+$317K	0.09%	132

Gabelli & Co Investment Advisers's OPNT Position: Q1 2023 in Review

Gabelli & Co Investment Advisers sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 20,700 shares — an estimated $420K sold.

Gabelli & Co Investment Advisers first reported a position in OPNT in Q4 2022 and held it in 1 quarter. The position peaked at $420K in Q4 2022. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

Gabelli & Co Investment Advisers reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 20,700 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $420K.
Gabelli & Co Investment Advisers first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
Gabelli & Co Investment Advisers's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $420K in Q4 2022.
0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2023, filed 12 May 2023.